Page de couverture de A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

Auteur(s): Annenberg Center for Health Sciences
Écouter gratuitement

À propos de cet audio

 In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.Annenberg Center for Health Sciences Hygiène et mode de vie sain Troubles et maladies
Épisodes
  • Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

    Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
    Jun 9 2022

    Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
    Voir plus Voir moins
    8 min
  • Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    Jun 9 2022

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    Voir plus Voir moins
    37 min
  • Disease Burden and Overview of Large B-Cell Lymphomas

    Disease Burden and Overview of Large B-Cell Lymphomas
    Jun 9 2022

    B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.  
    Voir plus Voir moins
    4 min
Pas encore de commentaire